Fingolimod (FTY720) è un nuovo agente immunomodulante orale attualmente in fase di valutazione per il trattamento della sclerosi multipla recidivante. In questo studio proof-of-concept ...

FTY720 is a structural analogue of sphingosine that, after conversion to the biologically active FTY720-phosphate molecule, binds with high affinity to sphingosine-1-phosphate receptors to act as ...

Impact of AKT inhibitor MK-2206 on erlotinib resistance in non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I. This abstract does not include a ...

Oral fingolimod (FTY720) is a sphingosine-1-phosphate–receptor modulator. After phosphorylation, fingolimod acts as a functional antagonist of the sphingosine-1-phosphate type 1 receptor ...

ZURICH, Sept 30 (Reuters) - Swiss drugmaker Novartis AG said on Wednesday its FTY720 oral drug to treat multiple sclerosis reduced both relapses and disability progression. Initial results from ...

Combined data from TRANSFORMS and FREEDOMS studies show significant efficacy in reducing relapses, disability progression and MRI lesions in MS - In FREEDOMS, FTY720 0.5 mg dose reduced the risk ...

A new study finds that brief preexposure of the ovaries to an FDA-approved agent called FTY720 preserved the fertility of female rhesus monkeys exposed to potentially lethal doses of radiation.

Published today in Autophagy, the researchers found the drug (FTY720) had a potent effect in human ovarian cancer cells, even in those resistant to cisplatin, the most commonly used ...